New Zealand markets closed

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.19-0.17 (-2.67%)
At close: 4:00PM EDT
6.25 +0.06 (+0.97%)
After hours: 05:29PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5127.36M
Enterprise value 397.29M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)7.72
Price/book (mrq)2.86
Enterprise value/revenue 35.19
Enterprise value/EBITDA 7-23.25

Trading information

Stock price history

Beta (5Y monthly) -0.16
52-week change 3-19.85%
S&P500 52-week change 333.64%
52-week high 333.34
52-week low 35.05
50-day moving average 36.51
200-day moving average 37.41

Share statistics

Avg vol (3-month) 3441.83k
Avg vol (10-day) 353.37k
Shares outstanding 519.35M
Implied shares outstanding 6N/A
Float 817.37M
% held by insiders 16.86%
% held by institutions 17.48%
Shares short (29 Sep 2021) 4448.18k
Short ratio (29 Sep 2021) 44.43
Short % of float (29 Sep 2021) 4N/A
Short % of shares outstanding (29 Sep 2021) 42.32%
Shares short (prior month 30 Aug 2021) 4566.39k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 322 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 29 Apr 2021
Most-recent quarter (mrq)30 Jul 2021

Profitability

Profit margin -53.49%
Operating margin (ttm)-49.62%

Management effectiveness

Return on assets (ttm)-11.88%
Return on equity (ttm)-26.60%

Income statement

Revenue (ttm)18.73M
Revenue per share (ttm)1.06
Quarterly revenue growth (yoy)21.90%
Gross profit (ttm)11.4M
EBITDA -7.6M
Net income avi to common (ttm)-10.02M
Diluted EPS (ttm)-0.46
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)40.7M
Total cash per share (mrq)2.1
Total debt (mrq)3.29M
Total debt/equity (mrq)5.93
Current ratio (mrq)7.08
Book value per share (mrq)2.88

Cash flow statement

Operating cash flow (ttm)-1.97M
Levered free cash flow (ttm)-2.05M